Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Special veg-rich diet may slow cognitive decline in elderly, study shows

A diet rich in green leafy vegetables, beans, berries, whole grains and wine can help to slow normal brain aging and cognitive decline, researchers said on Tuesday. Cognitive decline is a normal part of aging but a study by scientists at Rush University Medical Center in Chicago showed that elderly adults who strictly followed the […]

Read More »

Lilly to End Contract with the University of California, San Diego for A4 Alzheimer’s Study

INDIANAPOLIS, Aug. 4, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today notified the University of California, San Diego (UCSD) of its intent to end its contract with the university for the management of the Anti-amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study. The A4 study is a novel clinical trial testing solanezumab in the […]

Read More »

CDC modeling projects growth of drug-resistant infections and C. difficile

ATLANTA, Aug. 4, 2015 /PRNewswire-USNewswire/ — The latest CDC Vital Signs includes mathematical modeling that projects increases in drug-resistant infections and Clostridium difficile (C. difficile) without immediate, nationwide improvements in infection control and antibiotic prescribing. The promising news is that CDC modeling projects that a coordinated approach—that is, health care facilities and health departments in […]

Read More »

U.S. health regulator issues new cleaning guide for superbug-prone device

Hospitals that can afford it should take steps beyond those recommended by the manufacturer to clean and disinfect a type of device at the center of a recent superbug outbreak in the United States, health regulators said on Tuesday. Health care facilities that use duodenoscopes should meticulously follow the manufacturer’s cleaning instructions, the Food and […]

Read More »

FDA to revise Novartis’ Gilenya label to reflect brain infection risk

The U.S. Food and Drug Administration said it will update the label of Novartis AG’s multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. A case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported with the use of the drug, a first […]

Read More »

Why Did My Grandmother Try LSD For Multiple Sclerosis In The 1960s? 

Last year, LSD took a tentative, presumably groovy step back into the medical limelight when it was the featured performer in a controlled human trial for the first time in 40 years. Its redebut involved a role as an anti-anxiety drug in 12 patients in Switzerland, most of them with cancer, and marked a new […]

Read More »

A New Ebola Vaccine Is Related To Rabies. Is It Safe?

An experimental vaccine offers total protection against Ebola, according to preliminary results from a large clinical trial. Among 4,000 vaccinated people, there were no cases of infection. The study concluded that the vaccine – known as ‘rVSV-ZEBOV’ – is “highly efficacious and safe in preventing Ebola virus disease”. Here’s all you need to know about […]

Read More »

IRS Seeks Public Comment On Controversial Obamacare Cadillac Tax

When the The Patient Protection and Affordable Care Act (often just referred to as “Obamacare”) took effect, one of the most controversial features was the so-called Cadillac tax. The tax was intended to target high cost health care plans, thus earning the moniker “Cadillac.” The tax hasn’t changed much since it was first dreamed up. It’s […]

Read More »

Mallinckrodt Profit Surges as Acquisitions Drive Sales

Pharmaceutical company Mallinckrodt PLC said its profit soared in the latest quarter as the company’s specialty brand sales continue to benefit from recent acquisitions. But overall sales missed analysts’ lofty expectations, and shares slid 10.4% in midday trading—hitting a six-month low and giving up nearly half of the stock’s gain this year. In March, the […]

Read More »

Potential FDA Approval of Pink Viagra Sends Wrong Message

SEATTLE, Aug. 4, 2015 /PRNewswire/ — Dr. Keesha Ewers of The Functional Sexology Institute states the potential FDA approval of flibanserin, or what is being touted as “pink Viagra,” sets women and the treatment of decreased female sexual desire back several decades. Diminished libido in women has many root causes and addressing libido as a singular […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom